List of selected publications
Khazan-Kost, S., Cafri, G., Melamed Kadosh, D., Mooshayef, N., Chatterji, S., Dominissini, D., Manor, S., Zisser, B., Broday, L., Talalai, E., Shemer, A., Zadok, O., Ofek, E., Onn, A., Admon, A., and Peled, M. (2022) Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens. J. Immunother. cancer 10, e003733
Komov, L., Kadosh, D. M., Barnea, E., and Admon, A. (2021) The effect of interferons on presentation of defective ribosome products as HLA peptides. Mol. Cell. Proteomics, 100105
Admon, A. (2021) Are there indeed spliced peptides in the immunopeptidome? Mol. Cell. Proteomics, 100099
Rijensky, N. M., Blondheim Shraga, N. R., Barnea, E., Peled, N., Rosenbaum, E., Popovtzer, A., Stemmer, S. M., Livoff, A., Shlapobersky, M., Moskovits, N., Perry, D., Rubin, E., Haviv, I., and Admon, A. (2020) Identification of tumor antigens in the HLA peptidome of patient-derived xenograft tumors in mouse. Mol. Cell. Proteomics 19, mcp.RA119.001876
Shraibman, B., Barnea, E., Kadosh, D. M., Haimovich, Y., Slobodin, G., Rosner, I., López-Larrea, C., Hilf, N., Kuttruff, S., Song, C., Britten, C., Castle, J., Kreiter, S., Frenzel, K., Tatagiba, M., Tabatabai, G., Dietrich, P.-Y. Y., Dutoit, V., Wick, W., Platten, M., Winkler, F., Von Deimling, A., Kroep, J., Sahuquillo, J., Martinez-Ricarte, F., Rodon, J., Lassen, U., Ottensmeier, C., Van Der Burg, S. H., Straten, P. T., Poulsen, H. S., Ponsati, B., Okada, H., Rammensee, H.-G. G., Sahin, U., Singh, H., Admon, A., Thor Straten, P., Poulsen, H. S., Ponsati, B., Okada, H., Rammensee, H.-G. G., Sahin, U., Singh, H., Admon, A., Straten, P. T., Poulsen, H. S., Ponsati, B., Okada, H., Rammensee, H.-G. G., Sahin, U., Singh, H., Admon, A., Deimling, A. von, Kroep, J., Sahuquillo, J., Martinez-Ricarte, F., Rodon, J., Lassen, U., Ottensmeier, C., Burg, S. H. van der, Straten, P. T., Poulsen, H. S., Ponsati, B., Okada, H., Rammensee, H.-G. G., Sahin, U., Singh, H., and Admon, A. (2019) Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Mol. Cell. Proteomics 18, 1255–1268
Admon, A. (2019) ERAP1 shapes just part of the immunopeptidome. Hum. Immunol. 80, 296–301
Yair-Sabag, S., Tedeschi, V., Vitulano, C., Barnea, E., Glaser, F., Melamed Kadosh, D., Taurog, J. D. J. D., Fiorillo, M. T. M. T., Sorrentino, R., and Admon, A. (2018) The Peptide Repertoire of HLA-B27 may include Ligands with Lysine at P2 Anchor Position. Proteomics 18, e1700249
Komov, L., Kadosh, D. M., Barnea, E., Milner, E., Hendler, A., and Admon, A. (2018) Cell Surface MHC Class I Expression Is Limited by the Availability of Peptide-Receptive “Empty” Molecules Rather than by the Supply of Peptide Ligands. Proteomics 18, e1700248
Barnea, E., Melamed Kadosh, D., Haimovich, Y., Satumtira, N., Dorris, M. L., Nguyen, M. T., Hammer, R. E., Tran, T. M., Colbert, R. A., Taurog, J. D., and Admon, A. (2017) The Human Leukocyte Antigen (HLA)-B27 Peptidome in Vivo, in Spondyloarthritis-susceptible HLA-B27 Transgenic Rats and the Effect of Erap1 Deletion. Mol. Cell. Proteomics. 16, 642–662
Kalaora, S., Barnea, E., Merhavi-Shoham, E., Qutob, N., Teer, J. K., Shimony, N., Schachter, J., Rosenberg, S. A., Besser, M. J., Admon, A., and Samuels, Y. (2016) Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget. 7, 5110–7
Shraibman, B., Kadosh, D. M., Barnea, E., and Admon, A. (2016) Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy. Mol. Cell. Proteomics. 15, 3058–70
Bourdetsky, D., Schmelzer, C. E. H., and Admon, A. (2014) The nature and extent of contributions by defective ribosome products to the HLA peptidome. Proc. Natl. Acad. Sci. U. S. A. 111, E1591–E1599
Milner, E., Gutter-Kapon, L., Bassani-Strenberg, M., Barnea, E., Beer, I., and Admon, A. (2013) The effect of proteasome inhibition on the generation of the human leukocyte antigen (HLA) peptidome. Mol. Cell. Proteomics. 12, 1853–64
Admon, A., and Bassani-Sternberg, M. (2011) The Human Immunopeptidome Project, a Suggestion for yet another Postgenome Next Big Thing. Mol. Cell. Proteomics. 10, O111.011833
Ben Dror, L., Barnea, E., Beer, I., Mann, M., Admon, A., Dror, L. Ben, Barnea, E., Beer, I., Mann, M., Admon, A., Ben Dror, L., Barnea, E., Beer, I., Mann, M., and Admon, A. (2010) The HLA-B*2705 peptidome. Arthritis Rheum. 62, 420–429
Bassani-Sternberg, M., Barnea, E., Beer, I., Avivi, I., Katz, T., and Admon, A. (2010) Soluble plasma HLA peptidome as a potential source for cancer biomarkers. Proc Natl Acad Sci U S A. 107, 18769–18776
Milner, E., Barnea, E., Beer, I., and Admon, A. (2006) The turnover kinetics of major histocompatibility complex peptides of human cancer cells. Mol. Cell. Proteomics. 5, 357–65
Buchsbaum, S., Barnea, E., Dassau, L., Beer, I., Milner, E., and Admon, A. (2003) Large-scale analysis of HLA peptides presented by HLA-Cw4. Immunogenetics. 55, 172–176
Admon, A., Barnea, E., and Ziv, T. (2003) Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides. Mol. Cell. Proteomics. 2, 388–98
Barnea, E., Beer, I., Patoka, R., Ziv, T., Kessler, O., Tzehoval, E., Eisenbach, L., Zavazava, N., and Admon, A. (2002) Analysis of endogenous peptides bound by soluble MHC class I molecules: A novel approach for identifying tumor-specific antigens. Eur. J. Immunol. 32, 213–222
